Abstract:Background Yttrium‐90 (90Y) positron emission tomography (PET)/computed tomography (CT) imaging is increasingly being used to perform tumor (T) and normal liver (NL) voxel dosimetry after 90Y‐radioembolization (90Y‐RE). Yet, the accuracy of in vivo 90Y‐PET/CT imaging, subject to motion blur and co‐registration inaccuracies, and 90Y‐PET/CT dose quantification, subject to availability of different voxel dosimetry algorithms, are not well understood. Purpose The purpose of this study was to investigate the accuracy of 90Y‐PET/CT‐based activity estimates following 90Y‐RE and characterize differences between 90Y‐PET/CT‐based voxel dosimetry algorithms. Methods Thirty‐five patients underwent 90Y‐PET/CT imaging after 90Y‐RE with TheraSphere. The net administered 90Y activity (Aadmin) was determined using a dose calibrator and pre‐ and post‐procedure exposure rate measurements. The summation of image‐based activity (Aimage) was extracted from perfused volume (PV) and 3D‐isotropically 2‐cm expanded PV contour (PV+2 cm). Absorbed doses were calculated using voxel S‐value (VSV), local deposition method (LDM), and LDM with known activity (LDMKA) dosimetry algorithms. Linear regression and Bland‐Altman analysis quantified the relationship between Aimage and Aadmin and between mean dose estimates (DLDM, DVSV, DLDM‐KA) for PV, T, and perfused NL volumes. Results While Aadmin and Aimage in PV were highly correlated (R2 > 0.95), the mean bias ± standard error (SE) and (95% limits of agreement, LOA) was significantly non‐zero with −22.7 ± 4.7% (± 28.4%). In PV+2 cm, the mean bias ± SE (± LOA) decreased to 1.3 ± 3.4% (± 18.0%) consistent with zero mean error. DLDM and DVSV were highly correlated (R2 > 0.99) for all volumes of interest (VOIs) and the mean bias ± SE (± LOA) was 2.2 ± 0.2% (± 1.0%), 0.7 ± 0.4% (± 2.8%), and 3.2 ± 0.5% (± 2.8%) for PV, T, and NL, respectively. DLDM‐KA and DVSV were correlated with R2 = 0.86, 0.80, and 0.86 for PV, T, and NL, respectively. The mean bias ± SE (± LOA) between DLDM‐KA and DVSV was significantly non‐zero with −19.6 ± 5.1% (± 31.0%), −20.8 ± 4.4% (± 29.0%), and −18.1 ± 5.3% (± 31.1%) for PV, T, and NL, respectively. Conclusions The summation of Aimage in PV was underestimated relative to Aadmin. Only by accounting for respiratory motion, limited spatial resolution, and PET/CT co‐registration errors through VOI expansion was Aimage, on average, equal to Aadmin. The differences between DLDM and DVSV were not clinically relevant, though DLDM‐KA was approximately 20% greater than DVSV. Given the high quantitative accuracy of dose calibrators and challenges associated with accurate 90Y‐PET/CT quantification, LDMKA is the preferred algorithm for accurate 90Y‐PET/CT‐based dosimetry following 90Y‐RE.

PET/CT and SPECT/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: Anthropomorphic phantom study

Phantom study for 90 Y liver radioembolization dosimetry with a long axial field-of-view PET/CT

Yttrium-90-labeled microsphere tracking during liver selective internal radiotherapy by bremsstrahlung pinhole SPECT: feasibility study and evaluation in an abdominal phantom

Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer

Measure of 90Y-glass microspheres residue post-TARE using PET/CT and potential impact on tumor absorbed dose in comparison 99mTc-MAA SPECT/CT dosimetry

Phantom study for 90Y post-treatment dosimetry with a long axial field-of-view PET/CT

Quantification performance of silicon photomultiplier-based PET for small 18F-, 68Ga- and 124I-avid lesions in the context of radionuclide therapy planning

A comparison of methods for in vivo activity and absorbed dose quantification with PET/CT following yttrium‐90 radioembolization

Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model.

A Technical Perspective on Same-Day Radioembolization

Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation

177Lu SPECT imaging in the presence of90Y: does90Y degrade image quantification? a simulation study

Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts?

Quantitative evaluation of 90Y‐PET/CT and 90Y‐SPECT/CT‐based dosimetry following Yttrium‐90 radioembolization

Experimental Study on Roles of 99Mtc-Hl91 Imaging and Carbogen Breathing in 32P-Colloid Interstitial Treatment of Malignant Tumor

Liver Radioembolization: Predicting Lung Shunt Fraction with Contrast-Enhanced CT, Eliminating the Need for 99mTc-MAA

Predictive Dosimetry and Outcomes of Hepatocellular Carcinoma Treated by Y90 Resin Microsphere Radioembolization: A Retrospective Analysis Using 99mTC-MAA SPECT/CT and Planning Software

Tumor Response Prediction in 90Y Radioembolization with PET-based Radiomics Features and Absorbed Dose Metrics

Yttrium-90 TOF-PET based EUD predicts response post liver radioembolizations using standard manufacturer reconstruction parameters

An international phantom study of inter-site variability in Technetium-99m image quantification: analyses from the TARGET radioembolization study

PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI